TABLE 4.

Molecular characteristics of 25 observed treatment failures during therapeutic efficacy studies in Zaire and Uíge Provinces, Angola, in 2013

Patient ID no.	Treatment arma	Classificationb	MOIc	Resistance marker(s) on day 0 and day of failured
				pfmdr1e		SNPf		K13
				CN	Haplotype	Chr 10	Chr 13
B313g	AL-Z	ETF	2	1	NYD	wt	wt	wt
A111	AL-U	RECR	1	1	NFD	wt	wt	wt
A145	AL-U	RECR	1	1	NYD	wt	wt	wt
B314	AL-Z	RECR	1	1	NYD	wt	wt	wt
B384	AL-Z	RECR	1	1	NYD	wt	wt	wt
B385	AL-Z	RECR	2	1	NFD	wt	wt	wt
B399	AL-Z	RECR	2	1	NFD	wt	wt	wt
B404	AL-Z	RECR	2	1	NFD	wt	wt	wt
B416	AL-Z	RECR	2	1	NYD	wt	wt	wt
B422	AL-Z	RECR	2/1	1	NYD+NFD/NYD	wt	wt	wt
A114	AL-U	REIN	1	1	NYD	wt	wt	wt
A115	AL-U	REIN	2/1	1	YFD/YYD	wt	wt	wt
A144	AL-U	REIN	4/1	1	NYD	wt	wt	wt
A171	AL-U	REIN	1/2	1	YYD/NFD	wt	wt	wt
B304	AL-Z	REIN	1	1	NFD	wt	wt	wt
B312	AL-Z	REIN	1	1	NYD	wt	wt	wt
B371	AL-Z	REIN	2	1	NFD	wt	wt	wt
B375	AL-Z	REIN	1/2	1	NFD/YYD	wt	wt	wt
B386	AL-Z	REIN	1	1	YYY/NYD	wt	wt	wt
B387	AL-Z	REIN	1	1	NFY/NYD	wt	wt	wt
B398	AL-Z	REIN	1	1	NYD	wt	wt	wt
B402	AL-Z	REIN	2/1	1	YYY/NYD	wt	wt	wt
B421	AL-Z	REIN	1/2	1	NYD/NFD	wt	wt	wt
B423	AL-Z	REIN	1/2	1	NFD/NYD	wt	wt	wt
C560	DP-Z	REIN	1	1	YYD	wt	wt	wt

^aAL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine; Z, Zaire; U, Uíge.

^bETF, early treatment failure; RECR, recrudescence; REIN, reinfection.

^cMultiplicities of infection (MOI) either are the same for day 0 and the day of failure or are reported as day 0 MOI/day of failure MOI.

^dResistance markers either are the same for day 0 and the day of failure or are reported as day 0/day of failure. wt, wild type.

^e“CN” represents the P. falciparum multidrug resistance gene 1 copy number, and “haplotype” represents the haplotype constructed from mutations N86Y, Y184F, and D1246Y.

^fShown are the chromosome 10 (Chr 10) SNP at position 688956 and Chr 13 SNP at position 1718319 associated with artemisinin resistance.

^gMolecular data for early treatment failure are available for day 0 only.